Please ensure Javascript is enabled for purposes of website accessibility

Why Arcus Biosciences, Eldorado Gold, and Esperion Therapeutics Slumped Today

By Dan Caplinger - Updated Apr 12, 2019 at 4:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even in a surging market, these stocks fell. Find out why.

Wall Street had a big celebration on Friday, and stocks soared in the wake of news that the U.S. economy appears to remain strong. Positive data from the monthly jobs report sent major indexes up 3% to 4%, regaining all of their losses from Thursday's down session. Yet some stocks missed out on the market's overall gains, and Arcus Biosciences (RCUS 2.28%), Eldorado Gold (EGO 3.49%), and Esperion Therapeutics (ESPR 2.86%) were among the worst performers. Here's why they did so poorly.

Arcus sees an executive departure

Shares of Arcus Therapeutics were down 14% after the biopharmaceutical company announced changes in its executive team. The company said that Jennifer Jarrett, who has held the dual role of chief financial and operating officer, would step down effective Jan. 11. Jarrett will remain on the Arcus board, but she intends to work with a privately held transportation and technology company. As often happens with unexpected executive moves, shareholders seem to be drawing negative conclusions from Jarrett’s departure, but the executive was quick to express her confidence in Arcus' prospects in the high-growth cancer immunotherapy sector.

Falling stock chart superimposed over columns of blue numbers

Image source: Getty Images.

Eldorado looks a little less golden

Eldorado Gold's stock dropped nearly 6% on a poor day for the gold market. Even with most other financial markets seeing big gains, gold prices fell $9 to $1,285 per ounce, and more importantly, the strength of the U.S. economy removed some of the incentive for investors to hold what's perceived as a safe-haven asset. For Eldorado, volatility in gold prices has contributed to big swings in both directions recently, but shareholders today clearly think that a strong economy is bad for gold mining companies like Eldorado.

Check out the latest Eldorado Gold earnings call transcript.

Esperion makes a deal

Finally, shares of Esperion Therapeutics finished lower by 6%. The company had initially seen a big jump after announcing an agreement with Daiichi Sankyo Europe to market its bempedoic acid treatment in Europe. Under the deal, Esperion will receive $300 million up front as well as the potential for up to $900 million more in milestone payments. Yet after the initial gain, investors seemed to sour on the deal, perhaps thinking that Esperion would have done better to go it alone in hopes of reaping the full benefit of a hoped-for FDA approval in the near future.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eldorado Gold Corporation Stock Quote
Eldorado Gold Corporation
$7.11 (3.49%) $0.24
Esperion Therapeutics Stock Quote
Esperion Therapeutics
$6.47 (2.86%) $0.18
Arcus Biosciences, Inc. Stock Quote
Arcus Biosciences, Inc.
$25.55 (2.28%) $0.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.